Clinical Trial Update: Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ [NA]

View source ↗

Summary

A completed NCI-sponsored trial evaluating lapatinib ditosylate in HER2-positive ductal carcinoma in situ, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ductal Breast Carcinoma In Situ, HER2/Neu Positive | NA | Status: COMPLETED | Results posted: 2015-11-25